Celldex Shares Fall After Barzolvolimab Fails Phase 2 Atopic Dermatitis Trial
Celldex Therapeutics (CLDX) shares declined approximately 2% in after-hours trading following the announcement that its phase 2 clinical trial for barzolvolimab failed to meet both primary and secondary endpoints. The study focused on treating atopic dermatitis, specifically measuring efficacy through the Peak Pruritus Numerical Rating Scale (PP-NRS). The failure of this trial represents a setback for Celldex's pipeline development in the dermatological space. Investors are reacting to the lack of clinical significance demonstrated by the drug in achieving its intended goals regarding itch reduction and skin improvement.

Tickers: $CLDX
Topics: atopic dermatitis clinical trial failure stock price movement